KEY CLINICAL DATA ABOUT KLISYRI®:
A MODERN APPROACH TO THE FIELD TREATMENT OF ACTINIC KERATOSIS
Explore the evidence
AAD
recommendation
Find out why the American Academy of Dermatology (AAD) Guidelines of Care for the Management of Actinic Keratosis (AK) have been updated to include a strong recommendation with a high certainty of evidence for tirbanibulin (KLISYRI®)—the only topical field therapy to receive such a recommendation.1
clinical trial
published in nejm
See results from the Phase 3 Trials of Tirbanibulin (KLISYRI®) Ointment for Actinic Keratosis—the largest pivotal clinical trial program for a topical AK treatment—as published in the New England Journal of Medicine. 2,3
Real-world
evidence: PROAK
Explore the patient- and clinician-reported outcomes from PROAK®—as published in SKIN The Journal of Cutaneous Medicine and the Journal of Drugs in Dermatology. Learn more about this single-arm, prospective, real-world cohort study of adults with AKs on the face or scalp who were treated with KLISYRI® in clinical practice settings across the United States.4
PROAK=Patient and clinician Reported Outcomes for tirbanibulin effectiveness and safety in Actinic Keratosis.
IMPORTANT SAFETY INFORMATION
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com
References: 1. Eisen DB, Dellavalle RP, Frazer-Green L, et al. Focused update: guidelines of care for the management of actinic keratosis. JAAD. 2022;87(2). doi:https://doi.org/10.1016/j.jaad 2. Data on file. 2021. Pivotal Clinical Trials. 3. Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384:512-520. 4. Schlesinger T, Kircik L, Lebwohl M, et al. Patient- and clinician-reported outcomes for tirbanibulin in actinic keratosis in clinical practice across the United States (PROAK). J Drugs Dermatol. 2024;23(5):338-346. doi:10.36849/JDD/8264